OncLive |
Anti-CD20 Antibodies Continue to Improve Outlook in CLL
OncLive In 2006, Rituximab became the first anti-CD20 antibody to be approved for the treatment of hematologic malignancies and quickly became part of the armamentarium for the treatment of patients with CLL. “Ofatumumab was approved a few years ago, and … |
|
FDA to Evaluate Idelalisib for Indolent Non-Hodgkin’s Lymphoma
Monthly Prescribing Reference The NDA submission was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Idelalisib is an investigational … FDA Approves Application Review For Refractory Indolent Non-Hodgkin’s …BioResearch Online (press release) |
Pharmacy TimesRheumatoid Arthritis: Walking the WalkPharmacy TimesAccessed December 14, 2013. Rituximab: drug facts and comparisons. Facts & Comparisons database. St. Louis, MO: Wolters Kluwer Health, Inc; March 2005. Accessed December 14, 2013. Me…
|
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Teva Pharmaceutical …
Seeking Alpha Treanda, used for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing … |
|
FDA sets standard review for Gilead’s idelalisib in NHL
PMLiVE The marketing application in NHL was filed last September on the back of a single phase II trial in patients whose disease had progressed despite treatment with Roche and Biogen Idec’s Rituxan (rituximab) or conventional chemotherapy. Idelalisib … 3 Reasons to Buy Gilead Sciences, Inc.Motley Fool Standard Review for Gilead’s Oncology Candidate – Analyst BlogNASDAQ Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
MedscapeRituximab, Abatacept May Interfere With Influenza VaccineMedscapeMost arthritis treatments have no effect on the immunogenicity of adjuvanted pandemic H1N1 influenza (pH1N1) vaccine in patients with rheumatoid arthritis (RA) or spondyloarthropa…
|
Standard Review for Gilead’s Oncology Candidate
Yahoo News The patients were refractory to both Roche’s (OTC:RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology … |
|
3 Reasons to Buy Gilead Sciences, Inc.
Motley Fool Last December, Gilead announced that a late-stage trial for idelalisib was stopped early because patients receiving a combo of idelalisib plus rituximab showed a highly significant improvement in overall survival and progression-free survival. With the … Standard Review for Gilead’s Oncology Candidate – Analyst BlogNASDAQ Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
|
Standard Review for Gileads Oncology Candidate
Zacks.com The patients were refractory to both Roche’s (RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology … Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
Drug Discovery & Development |
Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartis
pharmabiz.com CTI is currently accruing patients into a phase III trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the United States. Opaxio (paclitaxel … Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 – UpdateNASDAQ Cell Therapeutics Inc : Cell Therapeutics Announces 2014 Outlook and Recent …4-traders (press release) |